Cargando…
LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma
Medulloblastoma (MB) is the most common type of brain cancer in pediatric patients. Body fluid biomarkers will be helpful for clinical diagnosis and treatment. In this study, liquid chromatography–mass spectrometry (LC–MS)-based metabolomics was used to identify specific urine metabolites of MB in a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353006/ https://www.ncbi.nlm.nih.gov/pubmed/35936679 http://dx.doi.org/10.3389/fonc.2022.949513 |
_version_ | 1784762777705906176 |
---|---|
author | Liu, Xiaoyan Li, Jing Hao, Xiaolei Sun, Haidan Zhang, Yang Zhang, Liwei Jia, Lulu Tian, Yongji Sun, Wei |
author_facet | Liu, Xiaoyan Li, Jing Hao, Xiaolei Sun, Haidan Zhang, Yang Zhang, Liwei Jia, Lulu Tian, Yongji Sun, Wei |
author_sort | Liu, Xiaoyan |
collection | PubMed |
description | Medulloblastoma (MB) is the most common type of brain cancer in pediatric patients. Body fluid biomarkers will be helpful for clinical diagnosis and treatment. In this study, liquid chromatography–mass spectrometry (LC–MS)-based metabolomics was used to identify specific urine metabolites of MB in a cohort, including 118 healthy controls, 111 MB patients, 31 patients with malignant brain cancer, 51 patients with benign brain disease, 29 MB patients 1 week postsurgery and 80 MB patients 1 month postsurgery. The results showed an apparent separation for MB vs. healthy controls, MB vs. benign brain diseases, and MB vs. other malignant brain tumors, with AUCs values of 0.947/0.906, 0.900/0.873, and 0.842/0.885, respectively, in the discovery/validation group. Among all differentially identified metabolites, 4 metabolites (tetrahydrocortisone, cortolone, urothion and 20-oxo-leukotriene E4) were specific to MB. The analysis of these 4 metabolites in pre- and postoperative MB urine samples showed that their levels returned to a healthy state after the operation (especially after one month), showing the potential specificity of these metabolites for MB. Finally, the combination of two metabolites, tetrahydrocortisone and cortolone, showed diagnostic accuracy for distinguishing MB from non-MB, with an AUC value of 0.851. Our data showed that urine metabolomics might be used for MB diagnosis and monitoring. |
format | Online Article Text |
id | pubmed-9353006 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93530062022-08-06 LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma Liu, Xiaoyan Li, Jing Hao, Xiaolei Sun, Haidan Zhang, Yang Zhang, Liwei Jia, Lulu Tian, Yongji Sun, Wei Front Oncol Oncology Medulloblastoma (MB) is the most common type of brain cancer in pediatric patients. Body fluid biomarkers will be helpful for clinical diagnosis and treatment. In this study, liquid chromatography–mass spectrometry (LC–MS)-based metabolomics was used to identify specific urine metabolites of MB in a cohort, including 118 healthy controls, 111 MB patients, 31 patients with malignant brain cancer, 51 patients with benign brain disease, 29 MB patients 1 week postsurgery and 80 MB patients 1 month postsurgery. The results showed an apparent separation for MB vs. healthy controls, MB vs. benign brain diseases, and MB vs. other malignant brain tumors, with AUCs values of 0.947/0.906, 0.900/0.873, and 0.842/0.885, respectively, in the discovery/validation group. Among all differentially identified metabolites, 4 metabolites (tetrahydrocortisone, cortolone, urothion and 20-oxo-leukotriene E4) were specific to MB. The analysis of these 4 metabolites in pre- and postoperative MB urine samples showed that their levels returned to a healthy state after the operation (especially after one month), showing the potential specificity of these metabolites for MB. Finally, the combination of two metabolites, tetrahydrocortisone and cortolone, showed diagnostic accuracy for distinguishing MB from non-MB, with an AUC value of 0.851. Our data showed that urine metabolomics might be used for MB diagnosis and monitoring. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9353006/ /pubmed/35936679 http://dx.doi.org/10.3389/fonc.2022.949513 Text en Copyright © 2022 Liu, Li, Hao, Sun, Zhang, Zhang, Jia, Tian and Sun https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Liu, Xiaoyan Li, Jing Hao, Xiaolei Sun, Haidan Zhang, Yang Zhang, Liwei Jia, Lulu Tian, Yongji Sun, Wei LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma |
title | LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma |
title_full | LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma |
title_fullStr | LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma |
title_full_unstemmed | LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma |
title_short | LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma |
title_sort | lc–ms-based urine metabolomics analysis for the diagnosis and monitoring of medulloblastoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353006/ https://www.ncbi.nlm.nih.gov/pubmed/35936679 http://dx.doi.org/10.3389/fonc.2022.949513 |
work_keys_str_mv | AT liuxiaoyan lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma AT lijing lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma AT haoxiaolei lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma AT sunhaidan lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma AT zhangyang lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma AT zhangliwei lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma AT jialulu lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma AT tianyongji lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma AT sunwei lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma |